Review finds limited clinical support for high-dose intravenous vitamin C
The review did not support routine use for sepsis, considered cancer applications exploratory, and found little clinical outcome evidence for home delivery. It also identified potentially serious harms.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
This review found different levels of support across medical settings. It did not support routine high-dose intravenous vitamin C for sepsis, while describing its cancer role as supportive and exploratory. Laboratory mechanisms and encouraging early clinical reports do not establish broad patient benefit, and the abstract highlights risks alongside limited evidence for home infusion.
Study counts, pooled clinical effects and methods for assessing bias are absent from the abstract. Conclusions about particular treatments or infusion settings therefore remain difficult to verify.
Cancer findings remain preliminary
Cancer evidence included early-phase studies reporting quality-of-life improvements and a pancreatic cancer trial reporting a survival benefit when vitamin C accompanied chemotherapy. The abstract gives no numerical benefit estimates or detailed comparison results.
Risks and delivery settings matter
Reported risks include kidney injury from oxalate and red blood cell breakdown in people with a particular enzyme deficiency. The review also found sparse outcome data for home infusions, leaving that delivery setting poorly evaluated.
The original publication
Clinical benefits and risks of high-dose intravenous vitamin C: a systematic review.
Alangari A, Arif J, Al Qureshah F et al.
J Med Life · 2026
- PubMed ID
- 41815850
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.